Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study

Babafemi Taiwo, Edward P. Acosta, Patrick Ryscavage, Baiba Berzins, Darlene Lu, Jay Lalezari, Jose G Castro, Oluwatoyin Adeyemi, Daniel R. Kuritzkes, Joseph J. Eron, Athe Tsibris, Susan Swindells

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

OBJECTIVE:: To address the need for nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens, we explored the virologic and pharmacokinetic characteristics of maraviroc plus ritonavir-boosted darunavir in a single-arm, open-label, 96-week study. METHODS:: Twenty-four antiretroviral-naive R5 HIV-1-infected participants received maraviroc 150 mg and darunavir/ritonavir (DRV/r) 800/100 mg (MVC/DRV/r) once daily. The primary outcome was virologic failure (VF) = confirmed viral load (VL) >50 copies per milliliter at week 24 in the modified intent-to-treat population. To determine viral dynamics, participant-specific first- and second-phase empirical Bayes estimates were compared with decay rates from efavirenz (EFV) plus lopinavir/ritonavir, lopinavir/ritonavir plus 2NRTIs, and EFV plus 2NRTIs. Maraviroc plasma concentrations were determined at weeks 2, 4, 12, 24, and 48. RESULTS:: Baseline median (Q1, Q3) CD4 count and VL were 455 (299, 607) cells per cubic millimeter and 4.62 (4.18, 4.80) log10 copies per milliliter, respectively. VF occurred in 3 of 24 participants {12.5% [95% confidence interval (CI): 2.7 to 32.4]} at week 24. One of these resuppressed, yielding a week 48 VF rate of 2/24 [8.3% (95% CI: 1.0 to 27.0)]. The week 48 failures were 2 of the 4 participants (50%) with baseline VL >100,000 copies per milliliter. Week 96 VF rate was 2/20 [10% (95% CI: 1.2 to 31.7)]. Phase 1 decay was faster with MVC/DRV/r than reported for ritonavir-boosted lopinavir plus 2NRTIs (P = 0.0063) and similar to EFV-based regimens. Individual maraviroc trough concentrations collected between 20 and 28 hours post dose (n = 59) was 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 ng/mL), and modeled steady-state concentration was 128 ng/mL. CONCLUSIONS:: MVC/DRV/r 150/800/100 mg once daily has potential for treatment-naive patients with R5 HIV-1.

Original languageEnglish
Pages (from-to)167-173
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume64
Issue number2
DOIs
StatePublished - Oct 1 2013

Fingerprint

Ritonavir
HIV-1
efavirenz
Pharmacokinetics
Lopinavir
Viral Load
Confidence Intervals
Reverse Transcriptase Inhibitors
Darunavir
maraviroc
CD4 Lymphocyte Count

Keywords

  • Darunavir
  • Maraviroc
  • Nucleos(t)ide sparing
  • Pharmacokinetics
  • Viral dynamics

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. / Taiwo, Babafemi; Acosta, Edward P.; Ryscavage, Patrick; Berzins, Baiba; Lu, Darlene; Lalezari, Jay; Castro, Jose G; Adeyemi, Oluwatoyin; Kuritzkes, Daniel R.; Eron, Joseph J.; Tsibris, Athe; Swindells, Susan.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 64, No. 2, 01.10.2013, p. 167-173.

Research output: Contribution to journalArticle

Taiwo, Babafemi ; Acosta, Edward P. ; Ryscavage, Patrick ; Berzins, Baiba ; Lu, Darlene ; Lalezari, Jay ; Castro, Jose G ; Adeyemi, Oluwatoyin ; Kuritzkes, Daniel R. ; Eron, Joseph J. ; Tsibris, Athe ; Swindells, Susan. / Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. In: Journal of Acquired Immune Deficiency Syndromes. 2013 ; Vol. 64, No. 2. pp. 167-173.
@article{b5f0c11d947e425da42fdefe77f9c3aa,
title = "Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study",
abstract = "OBJECTIVE:: To address the need for nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens, we explored the virologic and pharmacokinetic characteristics of maraviroc plus ritonavir-boosted darunavir in a single-arm, open-label, 96-week study. METHODS:: Twenty-four antiretroviral-naive R5 HIV-1-infected participants received maraviroc 150 mg and darunavir/ritonavir (DRV/r) 800/100 mg (MVC/DRV/r) once daily. The primary outcome was virologic failure (VF) = confirmed viral load (VL) >50 copies per milliliter at week 24 in the modified intent-to-treat population. To determine viral dynamics, participant-specific first- and second-phase empirical Bayes estimates were compared with decay rates from efavirenz (EFV) plus lopinavir/ritonavir, lopinavir/ritonavir plus 2NRTIs, and EFV plus 2NRTIs. Maraviroc plasma concentrations were determined at weeks 2, 4, 12, 24, and 48. RESULTS:: Baseline median (Q1, Q3) CD4 count and VL were 455 (299, 607) cells per cubic millimeter and 4.62 (4.18, 4.80) log10 copies per milliliter, respectively. VF occurred in 3 of 24 participants {12.5{\%} [95{\%} confidence interval (CI): 2.7 to 32.4]} at week 24. One of these resuppressed, yielding a week 48 VF rate of 2/24 [8.3{\%} (95{\%} CI: 1.0 to 27.0)]. The week 48 failures were 2 of the 4 participants (50{\%}) with baseline VL >100,000 copies per milliliter. Week 96 VF rate was 2/20 [10{\%} (95{\%} CI: 1.2 to 31.7)]. Phase 1 decay was faster with MVC/DRV/r than reported for ritonavir-boosted lopinavir plus 2NRTIs (P = 0.0063) and similar to EFV-based regimens. Individual maraviroc trough concentrations collected between 20 and 28 hours post dose (n = 59) was 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 ng/mL), and modeled steady-state concentration was 128 ng/mL. CONCLUSIONS:: MVC/DRV/r 150/800/100 mg once daily has potential for treatment-naive patients with R5 HIV-1.",
keywords = "Darunavir, Maraviroc, Nucleos(t)ide sparing, Pharmacokinetics, Viral dynamics",
author = "Babafemi Taiwo and Acosta, {Edward P.} and Patrick Ryscavage and Baiba Berzins and Darlene Lu and Jay Lalezari and Castro, {Jose G} and Oluwatoyin Adeyemi and Kuritzkes, {Daniel R.} and Eron, {Joseph J.} and Athe Tsibris and Susan Swindells",
year = "2013",
month = "10",
day = "1",
doi = "10.1097/QAI.0b013e3182a03d95",
language = "English",
volume = "64",
pages = "167--173",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study

AU - Taiwo, Babafemi

AU - Acosta, Edward P.

AU - Ryscavage, Patrick

AU - Berzins, Baiba

AU - Lu, Darlene

AU - Lalezari, Jay

AU - Castro, Jose G

AU - Adeyemi, Oluwatoyin

AU - Kuritzkes, Daniel R.

AU - Eron, Joseph J.

AU - Tsibris, Athe

AU - Swindells, Susan

PY - 2013/10/1

Y1 - 2013/10/1

N2 - OBJECTIVE:: To address the need for nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens, we explored the virologic and pharmacokinetic characteristics of maraviroc plus ritonavir-boosted darunavir in a single-arm, open-label, 96-week study. METHODS:: Twenty-four antiretroviral-naive R5 HIV-1-infected participants received maraviroc 150 mg and darunavir/ritonavir (DRV/r) 800/100 mg (MVC/DRV/r) once daily. The primary outcome was virologic failure (VF) = confirmed viral load (VL) >50 copies per milliliter at week 24 in the modified intent-to-treat population. To determine viral dynamics, participant-specific first- and second-phase empirical Bayes estimates were compared with decay rates from efavirenz (EFV) plus lopinavir/ritonavir, lopinavir/ritonavir plus 2NRTIs, and EFV plus 2NRTIs. Maraviroc plasma concentrations were determined at weeks 2, 4, 12, 24, and 48. RESULTS:: Baseline median (Q1, Q3) CD4 count and VL were 455 (299, 607) cells per cubic millimeter and 4.62 (4.18, 4.80) log10 copies per milliliter, respectively. VF occurred in 3 of 24 participants {12.5% [95% confidence interval (CI): 2.7 to 32.4]} at week 24. One of these resuppressed, yielding a week 48 VF rate of 2/24 [8.3% (95% CI: 1.0 to 27.0)]. The week 48 failures were 2 of the 4 participants (50%) with baseline VL >100,000 copies per milliliter. Week 96 VF rate was 2/20 [10% (95% CI: 1.2 to 31.7)]. Phase 1 decay was faster with MVC/DRV/r than reported for ritonavir-boosted lopinavir plus 2NRTIs (P = 0.0063) and similar to EFV-based regimens. Individual maraviroc trough concentrations collected between 20 and 28 hours post dose (n = 59) was 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 ng/mL), and modeled steady-state concentration was 128 ng/mL. CONCLUSIONS:: MVC/DRV/r 150/800/100 mg once daily has potential for treatment-naive patients with R5 HIV-1.

AB - OBJECTIVE:: To address the need for nucleos(t)ide reverse transcriptase inhibitor (NRTI)-sparing regimens, we explored the virologic and pharmacokinetic characteristics of maraviroc plus ritonavir-boosted darunavir in a single-arm, open-label, 96-week study. METHODS:: Twenty-four antiretroviral-naive R5 HIV-1-infected participants received maraviroc 150 mg and darunavir/ritonavir (DRV/r) 800/100 mg (MVC/DRV/r) once daily. The primary outcome was virologic failure (VF) = confirmed viral load (VL) >50 copies per milliliter at week 24 in the modified intent-to-treat population. To determine viral dynamics, participant-specific first- and second-phase empirical Bayes estimates were compared with decay rates from efavirenz (EFV) plus lopinavir/ritonavir, lopinavir/ritonavir plus 2NRTIs, and EFV plus 2NRTIs. Maraviroc plasma concentrations were determined at weeks 2, 4, 12, 24, and 48. RESULTS:: Baseline median (Q1, Q3) CD4 count and VL were 455 (299, 607) cells per cubic millimeter and 4.62 (4.18, 4.80) log10 copies per milliliter, respectively. VF occurred in 3 of 24 participants {12.5% [95% confidence interval (CI): 2.7 to 32.4]} at week 24. One of these resuppressed, yielding a week 48 VF rate of 2/24 [8.3% (95% CI: 1.0 to 27.0)]. The week 48 failures were 2 of the 4 participants (50%) with baseline VL >100,000 copies per milliliter. Week 96 VF rate was 2/20 [10% (95% CI: 1.2 to 31.7)]. Phase 1 decay was faster with MVC/DRV/r than reported for ritonavir-boosted lopinavir plus 2NRTIs (P = 0.0063) and similar to EFV-based regimens. Individual maraviroc trough concentrations collected between 20 and 28 hours post dose (n = 59) was 13.7 to 130 ng/mL (Q1, 23.4 ng/mL; Q3, 46.5 ng/mL), and modeled steady-state concentration was 128 ng/mL. CONCLUSIONS:: MVC/DRV/r 150/800/100 mg once daily has potential for treatment-naive patients with R5 HIV-1.

KW - Darunavir

KW - Maraviroc

KW - Nucleos(t)ide sparing

KW - Pharmacokinetics

KW - Viral dynamics

UR - http://www.scopus.com/inward/record.url?scp=84885207300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885207300&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e3182a03d95

DO - 10.1097/QAI.0b013e3182a03d95

M3 - Article

C2 - 23797691

AN - SCOPUS:84885207300

VL - 64

SP - 167

EP - 173

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 2

ER -